If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What are the recommended doses of EMGALITY® (galcanezumab-gnlm) and how is it administered?
The migraine prevention dose is 120 mg once monthly, with a 240 mg loading dose as the initial dose. The episodic cluster headache dose is 300 mg at the onset of the cluster period, and then monthly until the end of the cluster period.
Migraine Prevention Dosing
The recommended dose is 120-mg injected subcutaneously once monthly, following an initial 240-mg loading loading dose (administered as 2 consecutive injections of 120 mg each).1
Episodic Cluster Headache Dosing
The recommended dose is 300 mg, 3 consecutive injections of 100 mg each, injected subcutaneously monthly throughout a cluster period.1
Method of Administration
Galcanezumab is for subcutaneous administration.1 A patient may self-inject by following the instructions for use.
Sites for injection include the
- abdomen
- thigh
- back of the upper arm, and
- buttocks.1
Enclosed Prescribing Information
References
1Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Date of Last Review: January 24, 2022